PMID- 37102083 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230428 IS - 2352-5789 (Print) IS - 2352-5789 (Electronic) IS - 2352-5789 (Linking) VI - 47 DP - 2023 Jun TI - Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. PG - 101155 LID - 10.1016/j.gore.2023.101155 [doi] LID - 101155 AB - Mirvetuximab soravtansine (MIRV) is a first-in-class antibody-drug conjugate (ADC) targeting folate receptor alpha (FRalpha) and is indicated for the treatment of adult patients with FRalpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens. MIRV has demonstrated single-agent anticancer activity in clinical trials, with a differentiated safety profile comprising primarily low-grade, resolvable gastrointestinal and ocular adverse events (AEs). Pooled safety analysis of 464 MIRV-treated patients across 3 trials, including the phase 2 SORAYA study, found that 50% of patients had >/=1 ocular AEs of interest (AEIs) of blurred vision or keratopathy, the majority being grade /=2 AEIs of blurred vision and keratopathy resolved to grade 1 or 0 in patients with complete follow-up data. MIRV-associated ocular AEs were primarily characterized by resolvable changes to the corneal epithelium, with no cases of corneal ulcers or perforations. This reflects the distinctive, milder ocular safety profile for MIRV compared with that of other ADCs with ocular toxicities in clinical use. To maintain a generally low incidence of severe ocular AEs, patients should follow recommendations for maintaining ocular surface health, including daily use of lubricating eye drops and periodic use of corticosteroid eye drops, and should undergo an eye examination at baseline, at every other cycle for the first 8 cycles of treatment, and as clinically indicated. Dose modification guidelines should be followed to maximize patients' ability to remain on therapy. Close collaboration between all care team members, including oncologists and eye care professionals, will help patients benefit from this novel and promising anticancer agent. This review focuses on the etiology, rates, prevention, and management of MIRV-associated ocular events. CI - (c) 2023 The Authors. FAU - Hendershot, Andrew AU - Hendershot A AD - The Ohio State University Wexner Medical Center, Columbus, OH, USA. FAU - Slabaugh, Mark AU - Slabaugh M AD - The Ohio State University Wexner Medical Center, Columbus, OH, USA. FAU - Riaz, Kamran M AU - Riaz KM AD - Dean McGee Eye Institute, The University of Oklahoma College of Medicine, Oklahoma City, OK, USA. FAU - Moore, Kathleen N AU - Moore KN AD - Stephenson Cancer Center, The University of Oklahoma, Oklahoma City, OK, USA. FAU - O'Malley, David M AU - O'Malley DM AD - The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. FAU - Matulonis, Ursula AU - Matulonis U AD - Dana-Farber Cancer Institute, Boston, MA, USA. FAU - Konecny, Gottfried E AU - Konecny GE AD - UCLA Health, Los Angeles, CA, USA. LA - eng PT - Journal Article PT - Review DEP - 20230228 PL - Netherlands TA - Gynecol Oncol Rep JT - Gynecologic oncology reports JID - 101652231 PMC - PMC10123335 OTO - NOTNLM OT - Antibody-drug conjugates OT - Eye care OT - Folate receptor alpha OT - Mirvetuximab soravtansine OT - Ocular adverse events OT - Ovarian cancer COIS- The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: AH reports consulting/advising with ImmunoGen, Inc. MS reports consulting fees from ImmunoGen, Inc. KMR reports speaking fees from Bausch & Lomb Incorporated and CorneaGen; consulting/advising for Ambrx, Inc and ImmunoGen, Inc; and research support from ImprimisRx. KNM reports consulting/advising for Alkermes plc, Aravive, Inc, AstraZeneca PLC, Blueprint Medicines Corporation, Clovis Oncology, Inc, Eisai Co, Ltd, Elevar Therapeutics, Inc, Eli Lilly and Company, Genentech, Inc/Roche, GSK plc/TESARO Inc, I-MAB Biopharma Co, Ltd, ImmunoGen, Inc, InxMed Co, Ltd, Jiangsu Hengrui Pharmaceuticals Co, Ltd, Merck & Co, Inc, Mereo Biopharma Group PLC, Mersana Therapeutics, Inc, Myriad Genetics, Inc, Novartis, OncoMed Pharmaceuticals, Inc, Onconova Therapeutics, Inc, OncXerna Therapeutics, Inc, Tarveda Therapeutics, VBL Therapeutics, and Verastem, Inc; research funding from PTC Therapeutics, Eli Lilly and Company, GSK plc/TESARO Inc, and Merck & Co, Inc; associate directorship with GOG Partners; and participation in director's board for The GOG Foundation, Inc. DMO reports funding for clinical research from AbbVie Inc, Agenus Inc, Ajinomoto Co, Inc, Amgen Inc, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb Company, Clovis Oncology, Inc, Dare Bioscience, Inc, Eisai Co, Ltd, EMD Serono, Ergomed plc, Genentech, Inc, Genmab A/S, The GOG Foundation, Inc, ImmunoGen, Inc, Iovance Biotherapeutics, Inc, Janssen Biotech, Inc, Johnson & Johnson Pharmaceuticals, Ludwig Institute for Cancer Research Ltd, Merck & Co, Inc, Merck Serono, Mersana Therapeutics, Inc, New Mexico Cancer Care Alliance, Novocure GmbH, PRA Health Sciences, Regeneron Pharmaceuticals, Inc, Seagen Inc, Stemcentrx, Sumitomo Danippon Pharma Oncology, Inc, Syneos Health, TESARO Inc, TRACON Pharmaceuticals, Inc, VentiRx Pharmaceuticals, Inc, and Yale University; personal fees from Agenus Inc, Myriad Genetics, Inc, Rubius Therapeutics, Inc, and Tarveda Therapeutics; and fees for consulting or advisory boards from AbbVie Inc, Ambry Genetics Corporation, Amgen Inc, Arquer Diagnostics Ltd, AstraZeneca Pharmaceuticals LP, Celsion Corporation, Clovis Oncology, Inc, Corcept Therapeutics Incorporated, Eisai Co, Ltd, Elevar Therapeutics, Inc, Genentech, Inc, The GOG Foundation, Inc, ImmunoGen, Inc, InxMed Co, Ltd, Iovance Biotherapeutics, Inc, Janssen Biotech, Inc, Johnson & Johnson Pharmaceuticals, Merck & Co, Inc, Mersana Therapeutics, Inc, Novartis, Novocure GmbH, Regeneron Pharmaceuticals, Inc, Roche Diagnostics MSA, Seagen Inc, Sorrento Therapeutics, Inc, Sumitomo Danippon Pharma Oncology, Inc, Takeda Pharmaceuticals USA, Inc, TESARO Inc, and Toray Industries, Inc. UM reports consulting for Novartis, AstraZeneca PLC, Merck & Co, Inc, GSK plc, Trillium Therapeutics, Blueprint Medicines Corporation, Agenus Inc, and MorphoSys AG (all ongoing) and participating in scientific advisory boards for ImmunoGen, Inc, CureLab Oncology, NextCure, Inc, Ovarian Cancer Research Alliance, Rivkin Foundation, and Clearity Foundation (all ongoing) and in data and safety monitoring boards for Symphogen A/S, Alkermes plc, and Advaxis, Inc. GEK reports consulting for GSK plc/TESARO Inc; participating in advisory boards for GSK plc/Tissot, Clovis Oncology, Inc, ImmunoGen, Inc, and The GOG Foundation, Inc, in data and safety monitoring boards for RAPARE, and TORL Biotherapeutics, LLC, and in speakers bureau for AstraZeneca PLC, Merck & Co, Inc, and GSK/TESARO Inc; and research funding to the institution from Eli Lilly and Company and Merck & Co, Inc. EDAT- 2023/04/27 06:42 MHDA- 2023/04/27 06:43 PMCR- 2023/02/28 CRDT- 2023/04/27 02:15 PHST- 2023/01/12 00:00 [received] PHST- 2023/02/23 00:00 [revised] PHST- 2023/02/24 00:00 [accepted] PHST- 2023/04/27 06:43 [medline] PHST- 2023/04/27 06:42 [pubmed] PHST- 2023/04/27 02:15 [entrez] PHST- 2023/02/28 00:00 [pmc-release] AID - S2352-5789(23)00024-3 [pii] AID - 101155 [pii] AID - 10.1016/j.gore.2023.101155 [doi] PST - epublish SO - Gynecol Oncol Rep. 2023 Feb 28;47:101155. doi: 10.1016/j.gore.2023.101155. eCollection 2023 Jun.